EORTC-24051-HNCG

Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell.
Trial StatusAll trial activities ended
DatesDate of activation: 09-May-07
Closed on : 04-Nov-08
Data management at EORTCFull
Phase1-2
Randomized trial
TypeAdjuvant
Targeted Sample sizeEORTC Groups: - - All Groups: 127
Number of steps1
DrugFluorouracil
Carboplatin
Cisplatin
Docetaxel
Lapatinib
Study StaffAhmad Awada (Study Coordinator) - Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels
Jan Bogaerts (Statistician) - EORTC Headquarters, Brussels
Denis Lacombe (Coordinating Physician) - EORTC Headquarters, Brussels
Type of cancerHead and Neck
Participating GroupsEORTC Head and Neck Cancer Group(Coordinating Group)
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT00498953
EudraCT2006-002667-33
@
Back to Protocol section